company background image
OMCL logo

Omnicell NasdaqGS:OMCL Stock Report

Last Price

US$45.31

Market Cap

US$2.1b

7D

5.0%

1Y

39.4%

Updated

30 Jan, 2025

Data

Company Financials +

OMCL Stock Overview

Provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. More details

OMCL fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Omnicell, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Omnicell
Historical stock prices
Current Share PriceUS$45.31
52 Week HighUS$55.75
52 Week LowUS$25.12
Beta0.78
1 Month Change1.77%
3 Month Change-6.90%
1 Year Change39.42%
3 Year Change-70.17%
5 Year Change-48.12%
Change since IPO376.45%

Recent News & Updates

Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate

Jan 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate

Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues

Nov 27
Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues

Recent updates

Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate

Jan 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate

Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues

Nov 27
Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues

Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Nov 02
Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Omnicell Q3 Earnings: Look At The Growth Segment

Nov 01

Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Oct 31
Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Oct 07
Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%

Aug 02
Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%

Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?

Jul 11
Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Jun 16
Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt

May 25
Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Mar 28
An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 29
Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Feb 23
Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell Is Building A Strong Moat

Feb 22

Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Jan 15
Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Dec 25
Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Dec 06
Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Nov 10
Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Sep 06
Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

Aug 08
Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

Jul 02
Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Jun 08
A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Apr 29
Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Apr 11
Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Mar 23
At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Feb 28
Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

Jan 15
Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Jan 01
We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Nov 17
Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers

Nov 03
Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers

Omnicell launches Specialty Pharmacy Services

Oct 11

Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly

Sep 30
Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly

Omnicell says advance services to drive profitable growth in long-run: Investor Day

Sep 20

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Sep 15
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell (NASDAQ:OMCL) Might Have The Makings Of A Multi-Bagger

Aug 31
Omnicell (NASDAQ:OMCL) Might Have The Makings Of A Multi-Bagger

Shareholder Returns

OMCLUS Medical EquipmentUS Market
7D5.0%1.0%-0.5%
1Y39.4%14.4%24.3%

Return vs Industry: OMCL exceeded the US Medical Equipment industry which returned 15% over the past year.

Return vs Market: OMCL exceeded the US Market which returned 25.2% over the past year.

Price Volatility

Is OMCL's price volatile compared to industry and market?
OMCL volatility
OMCL Average Weekly Movement5.9%
Medical Equipment Industry Average Movement8.8%
Market Average Movement6.5%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: OMCL has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: OMCL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19923,660Randy Lippswww.omnicell.com

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software.

Omnicell, Inc. Fundamentals Summary

How do Omnicell's earnings and revenue compare to its market cap?
OMCL fundamental statistics
Market capUS$2.07b
Earnings (TTM)-US$17.69m
Revenue (TTM)US$1.06b

2.0x

P/S Ratio

-118.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OMCL income statement (TTM)
RevenueUS$1.06b
Cost of RevenueUS$623.24m
Gross ProfitUS$440.97m
Other ExpensesUS$458.66m
Earnings-US$17.69m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 06, 2025

Earnings per share (EPS)-0.38
Gross Margin41.44%
Net Profit Margin-1.66%
Debt/Equity Ratio46.5%

How did OMCL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 00:23
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Omnicell, Inc. is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
K. JuhngBB&T Capital Markets
William SutherlandBenchmark Company
Raymond MyersBenchmark Company